Humacyte Publishes Long-Term Data on Symvess with 92.9% Infection-Free Rate

Humacyte announced the publication of new, long-term data assessing the durability of Symvess in extremity arterial trauma patients in the Journal of Vascular Surgery Cases, Innovations and Techniques, JVS-CIT. The study, titled "Long-term Safety and Efficacy Outcomes of the Acellular Tissue Engineered Vessel, ATEV, in Extremity Arterial Trauma Repair" found that Symvess maintained structural integrity over the long term, exhibited low infection rates, and supported high rates of limb salvage in patients followed for up to 36 months. Among the patients treated in the V005 Phase 2/3 study were 54 patients who underwent extremity vascular repair with Symvess for whom treatment with autologous vein, the standard of care, was not feasible. Within this patient population, once early complications from the traumatic injuries resolved, the rates of conduit infection, limb salvage, and patient survival plateaued and remained relatively constant through the three years of follow-up. Symvess maintained an infection-free rate of 92.9% from months 3-36, with no infections after day 37 and only three conduit infections overall. Limb salvage rates were 87.3% at 12 months and 82.5% at 24 months, despite a severely injured trauma cohort.